research presentation on thyroid cancer
TRANSCRIPT
![Page 1: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/1.jpg)
Research PresentationResearch Presentation
Jason M. Leibowitz, MD
June 25, 2009
Preceptor: Marcia S. Brose, MD PhD
Jason M. Leibowitz, MD
June 25, 2009
Preceptor: Marcia S. Brose, MD PhD
Otorhinolaryngology: Head and Neck Surgery at PENN Excellence in Patient Care, Education and Research since 1870
![Page 2: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/2.jpg)
OverviewOverview
Background Hypothesis Methods Results Discussion Conclusions & Future Directions
Background Hypothesis Methods Results Discussion Conclusions & Future Directions
![Page 3: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/3.jpg)
Thyroid Cancer in the United StatesThyroid Cancer in the United States
Thyroid cancer is the most
common endocrine neoplasm.
Thyroid cancer will be diagnosed
in 33,550 individuals (8070 men
and 25,480 women) this year.
From 1997-2004 incidence of
thyroid cancer increased by 6.2%
mostly due to increased detection.
From 1985 to 2004 mortality rate
increased by 0.3% a year.
Thyroid cancer is the most
common endocrine neoplasm.
Thyroid cancer will be diagnosed
in 33,550 individuals (8070 men
and 25,480 women) this year.
From 1997-2004 incidence of
thyroid cancer increased by 6.2%
mostly due to increased detection.
From 1985 to 2004 mortality rate
increased by 0.3% a year.
![Page 4: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/4.jpg)
RAI-Refractory DiseaseRAI-Refractory Disease
25-50% of metastatic thyroid cancers lose ability to take up Iodine.
Iodine Uptake inversely correlates with survival. This is attributed to down regulation of the Na+/I-
Symporter (NIS). Limited treatment options for unresectable
thyroid cancer refractory to RAI.
25-50% of metastatic thyroid cancers lose ability to take up Iodine.
Iodine Uptake inversely correlates with survival. This is attributed to down regulation of the Na+/I-
Symporter (NIS). Limited treatment options for unresectable
thyroid cancer refractory to RAI.
![Page 5: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/5.jpg)
Molecular Changes in Thyroid Cancer
![Page 6: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/6.jpg)
Molecular Pathway involved in Thyroid Cancer
Molecular Pathway involved in Thyroid Cancer
Activation of MAPK pathway Oncogenic activation
of this pathway in 70% of all thyroid cancers.
BRAF is a serine threonine kinase
Activation of MAPK pathway Oncogenic activation
of this pathway in 70% of all thyroid cancers.
BRAF is a serine threonine kinase
Xing, 2007.
![Page 7: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/7.jpg)
BRAF V600E in Thyroid CancerBRAF V600E in Thyroid Cancer
2003: The BRAF V600E mutation is the most
common genetic alteration in thyroid cancer,
occurring in about 45% of sporadic papillary
thyroid cancers (PTCs).
2003: The BRAF V600E mutation is the most
common genetic alteration in thyroid cancer,
occurring in about 45% of sporadic papillary
thyroid cancers (PTCs).
V600E
![Page 8: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/8.jpg)
BRAF V600EBRAF V600E Point mutation in 40-45% of
PTC Upregulation of MMP, VEGF -->
invasion, angiogenesis Silencing of tumor suppressive
genes, genes involved in iodine transport
BRAF mutation associated with multiple negative prognostic indicators.
Point mutation in 40-45% of PTC Upregulation of MMP, VEGF -->
invasion, angiogenesis Silencing of tumor suppressive
genes, genes involved in iodine transport
BRAF mutation associated with multiple negative prognostic indicators.
![Page 9: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/9.jpg)
RASRAS
Family of small G-proteins involved in transduction of cellular signals from the cell membrane.
Mutations in RAS gene lead to inappropriate activation with constitutively activated downstream pathways and also promote chromosomal instability.
20% FTC contain a RAS mutation RAS mutations may correlate with aggressive behavior (tumor dedifferentiation and poorer prognosis).
Family of small G-proteins involved in transduction of cellular signals from the cell membrane.
Mutations in RAS gene lead to inappropriate activation with constitutively activated downstream pathways and also promote chromosomal instability.
20% FTC contain a RAS mutation RAS mutations may correlate with aggressive behavior (tumor dedifferentiation and poorer prognosis).
![Page 10: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/10.jpg)
Targeted Therapy in Thyroid cancer
Targeted Therapy in Thyroid cancer
Loss of differentiation (inability to trap RAI), unresectable lesion, leads to poor prognosis
BRAF inhibitors BAY 43-9006 (Sorafenib) Multikinase inhibitor
Loss of differentiation (inability to trap RAI), unresectable lesion, leads to poor prognosis
BRAF inhibitors BAY 43-9006 (Sorafenib) Multikinase inhibitor
![Page 11: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/11.jpg)
SorafenibSorafenib
Orally active multikinase inhibitor (study dose 400mg BID).
Monoclonal antibody with multiple targets including BRAF, VEGFR1, VEGFR2.
Blocks tumor cell proliferation and angiogenesis.
FDA approved for treatment of RCC and hepatocellular carcinoma.
Orally active multikinase inhibitor (study dose 400mg BID).
Monoclonal antibody with multiple targets including BRAF, VEGFR1, VEGFR2.
Blocks tumor cell proliferation and angiogenesis.
FDA approved for treatment of RCC and hepatocellular carcinoma.
![Page 12: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/12.jpg)
Targeted Therapy and GenotypeTargeted Therapy and Genotype
K-RAS gene mutation and metastatic colorectal carcinoma. Recent results from Phase II & III clinical trials demonstrate that
patients with metastatic colorectal cancer benefit from anti-EGFR therapy.
Patients with K-RAS mutation in codon 12 & 13 should not receive anti-EGFR therapy since they do not receive any benefit.
EGFR and non-small cell lung cancer: Epithelial growth factor receptor 10% mutated in NSCLC EGFR mutations are predictors of TKIs responsiveness and may
show a long lasting response to TKIs EXON 19 Deletion respond better to TKIs.
K-RAS gene mutation and metastatic colorectal carcinoma. Recent results from Phase II & III clinical trials demonstrate that
patients with metastatic colorectal cancer benefit from anti-EGFR therapy.
Patients with K-RAS mutation in codon 12 & 13 should not receive anti-EGFR therapy since they do not receive any benefit.
EGFR and non-small cell lung cancer: Epithelial growth factor receptor 10% mutated in NSCLC EGFR mutations are predictors of TKIs responsiveness and may
show a long lasting response to TKIs EXON 19 Deletion respond better to TKIs.
![Page 13: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/13.jpg)
Prior DataPrior Data
84 weeks
N= 52
N=43
WDTC
![Page 14: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/14.jpg)
Papillary vs. FollicularPapillary vs. Follicular
P<0.095FTC = 19
PTC= 24
![Page 15: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/15.jpg)
Prior DataPrior Data
Conclusions from prior data: Improved PFS with Sorafenib. Improved PFS of FTC treated with Sorafenib
when compared to PTC.
Conclusions from prior data: Improved PFS with Sorafenib. Improved PFS of FTC treated with Sorafenib
when compared to PTC.
![Page 16: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/16.jpg)
OverviewOverview
Background Hypothesis Methods Results Discussion Conclusions & Future Directions
Background Hypothesis Methods Results Discussion Conclusions & Future Directions
![Page 17: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/17.jpg)
HypothesisHypothesis
There are specific genotypes (i.e. BRAF V600E, RAS mutations) that predict favorable response to targeted therapy (Sorafenib).
There are specific genotypes (i.e. BRAF V600E, RAS mutations) that predict favorable response to targeted therapy (Sorafenib).
![Page 18: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/18.jpg)
Null HypothesisNull Hypothesis
Specific genetic mutations do not predict response to targeted therapy in thyroid cancer.
Specific genetic mutations do not predict response to targeted therapy in thyroid cancer.
![Page 19: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/19.jpg)
OverviewOverview
Background Hypothesis Methods Results Discussion Conclusions & Future Directions
Background Hypothesis Methods Results Discussion Conclusions & Future Directions
![Page 20: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/20.jpg)
Research PlanResearch Plan Tissue samples collected from patients with
treatment-resistant thyroid cancer with long term follow-up (approximately 30 patients).
All patients received targeted therapy (Sorafenib). Samples with WDTC analyzed for mutations in
BRAF and RAS genes when available: BRAF - V600E RAS - Exon 12, 13, 61
Tissue samples collected from patients with treatment-resistant thyroid cancer with long term follow-up (approximately 30 patients).
All patients received targeted therapy (Sorafenib). Samples with WDTC analyzed for mutations in
BRAF and RAS genes when available: BRAF - V600E RAS - Exon 12, 13, 61
![Page 21: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/21.jpg)
RESULTS
![Page 22: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/22.jpg)
Sequence OutputSequence Output Computer program interprets
data and produces an electropherogram, (aka trace)
Each peak represents a base: A = Adenosine T = Thymine C = Cytosine G = Guanine N = Reading cannot be
determined
Computer program interprets data and produces an electropherogram, (aka trace)
Each peak represents a base: A = Adenosine T = Thymine C = Cytosine G = Guanine N = Reading cannot be
determined
![Page 23: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/23.jpg)
OverviewOverview
Background Hypothesis Methods Results Discussion Conclusions & Future Directions
Background Hypothesis Methods Results Discussion Conclusions & Future Directions
![Page 24: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/24.jpg)
Results of Stage 1 AnalysisResults of Stage 1 Analysis•N= 30 •M = F = 15•PTC=17, FTC= 9, Other (ATC/PD, MTC): 4•Samples analyzed for BRAF mutation:
• 23/30 (76.6%): samples analyzed for BRAF mutation• 4/30 (13%): definite genotype but questioned due to phenotype
(ATC/PD, MTC)• 2/30 (6%): unable to amplify DNA despite multiple PCR attempts• 1/30 (3%): pending analysis
•18/30 samples analyzed for RAS mutation, all WT copies of the gene
•N= 30 •M = F = 15•PTC=17, FTC= 9, Other (ATC/PD, MTC): 4•Samples analyzed for BRAF mutation:
• 23/30 (76.6%): samples analyzed for BRAF mutation• 4/30 (13%): definite genotype but questioned due to phenotype
(ATC/PD, MTC)• 2/30 (6%): unable to amplify DNA despite multiple PCR attempts• 1/30 (3%): pending analysis
•18/30 samples analyzed for RAS mutation, all WT copies of the gene
![Page 25: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/25.jpg)
Results of Stage 1 AnalysisResults of Stage 1 Analysis
N=22 (interim analysis) 13 WT BRAF 9 BRAF V600E 16 PTC
9 WT BRAF, 7 V600E
6 FTC 4 WT BRAF, 2 V600E
N=22 (interim analysis) 13 WT BRAF 9 BRAF V600E 16 PTC
9 WT BRAF, 7 V600E
6 FTC 4 WT BRAF, 2 V600E
![Page 26: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/26.jpg)
BRAF V600EBRAF V600E
P<0.02
N=13 (WT=8,
V600E=5)
![Page 27: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/27.jpg)
Updated geneticsUpdated genetics In our expanded
analysis to 22 pts with WDTC, the effect is no longer significant but the trend exists.
We are further investigating BRAF copy number in these patients
In our expanded analysis to 22 pts with WDTC, the effect is no longer significant but the trend exists.
We are further investigating BRAF copy number in these patients
p=NS
N =22WT = 13BRAF V600E = 9
![Page 28: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/28.jpg)
OverviewOverview
Background Hypothesis Methods Results Discussion Conclusions & Future Directions
Background Hypothesis Methods Results Discussion Conclusions & Future Directions
![Page 29: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/29.jpg)
BRAFV600E Correlates with worse SurvivalBRAFV600E Correlates with worse Survival
Elisei et. al, J Clin Endocrinol Metab, October 2008, 93(10):3943–3949
![Page 30: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/30.jpg)
BRAFV600E Correlates with worse SurvivalState of the mutation in PTC, 10/2008
BRAFV600E Correlates with worse SurvivalState of the mutation in PTC, 10/2008
![Page 31: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/31.jpg)
THE BRAF connectionTHE BRAF connection
Ciampi et al. 2005
![Page 32: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/32.jpg)
Updated geneticsUpdated genetics In our expanded
analysis to 22 pts with WDTC, the effect is no longer significant but the trend exists.
We are further investigating BRAF copy number in these patients
In our expanded analysis to 22 pts with WDTC, the effect is no longer significant but the trend exists.
We are further investigating BRAF copy number in these patients
p=NS
N =22WT = 13BRAF V600E = 9
![Page 33: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/33.jpg)
BRAF (red) x 3
7 centromere (green) x 3
![Page 34: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/34.jpg)
BRAF x4
7 centromere x4
![Page 35: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/35.jpg)
4 copies each
3 copies each
![Page 36: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/36.jpg)
THE BRAF connection! Positive Predictor!
THE BRAF connection! Positive Predictor!
Ciampi et al, 2005.
![Page 37: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/37.jpg)
Future DirectionsFuture Directions
Completion of genotyping analysis of all patients
Evaluation of copy number gains in WDTC Hypothesis: Copy number gain accounts for
improved survival in FTC treated with Sorafenib
Null: Copy number gain does not influence survival in FTC
Completion of genotyping analysis of all patients
Evaluation of copy number gains in WDTC Hypothesis: Copy number gain accounts for
improved survival in FTC treated with Sorafenib
Null: Copy number gain does not influence survival in FTC
![Page 38: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/38.jpg)
Selected SourcesSelected Sources
Ciampi R, Zhu Z, Nikiforov YE. BRAF copy number gain in thyroid tumors detected by fluorescence in situ hybridization. Endocrine Pathology 2005; 16(2): 99-105.
Ciampi R, Nikiforov YE. Alterations of the BRAF gene in thyroid tumors. Endocrine Pathology 2005; 16:3): 163-171.
Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II Trial of Sorafenib in Advanced Thyroid Cancer. Journal Clin Onc 2008; 26 (29): 4714-4719.
Kundra P, Burman KD. Thyroid Cancer Molecular Signaling Pathways and Use of Targeted Therapy. Endoc Metab Clin N Am 2007;36: 839-853
Murer B. Targeted Therapy in Non-Small Cell Lung Cancer. Arch Path Lab Med. 2008; 132: 1573-1575.
Nikiforov YE. Thyroid Carcinoma: Molecular Pathways and Therapeutic targets. Modern Pathology 2008; 21: S37-S43.
Vasko V, Ferrand M, Cristofaro JD et al. Specific Pattern of RAS Oncogene Mutations in Follicular Thyroid Tumors. J. Clin Endocrin. & Metab. 2003; 88(6):2745-2752.
Xing M. BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Basis, and Clinical Implication. End Rev 2007; 28(7): 742-762.
Ciampi R, Zhu Z, Nikiforov YE. BRAF copy number gain in thyroid tumors detected by fluorescence in situ hybridization. Endocrine Pathology 2005; 16(2): 99-105.
Ciampi R, Nikiforov YE. Alterations of the BRAF gene in thyroid tumors. Endocrine Pathology 2005; 16:3): 163-171.
Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II Trial of Sorafenib in Advanced Thyroid Cancer. Journal Clin Onc 2008; 26 (29): 4714-4719.
Kundra P, Burman KD. Thyroid Cancer Molecular Signaling Pathways and Use of Targeted Therapy. Endoc Metab Clin N Am 2007;36: 839-853
Murer B. Targeted Therapy in Non-Small Cell Lung Cancer. Arch Path Lab Med. 2008; 132: 1573-1575.
Nikiforov YE. Thyroid Carcinoma: Molecular Pathways and Therapeutic targets. Modern Pathology 2008; 21: S37-S43.
Vasko V, Ferrand M, Cristofaro JD et al. Specific Pattern of RAS Oncogene Mutations in Follicular Thyroid Tumors. J. Clin Endocrin. & Metab. 2003; 88(6):2745-2752.
Xing M. BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Basis, and Clinical Implication. End Rev 2007; 28(7): 742-762.
![Page 39: Research Presentation on Thyroid Cancer](https://reader035.vdocuments.net/reader035/viewer/2022062406/558a25f4d8b42af3238b4725/html5/thumbnails/39.jpg)
ThanksThanks
Marcia Brose, MD PhD
Cathy Ma MD, PhD Kanchan Puttaswamy, MS
Marcia Brose, MD PhD
Cathy Ma MD, PhD Kanchan Puttaswamy, MS